Why the Creso Pharma (ASX:CPH) share price fell 9% before freezing

Creso Pharma shares came to a halt this afternoon, here's what is happening…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Creso Pharma Ltd (ASX: CPH) share price came under pressure this afternoon. This followed breaking news published by The Australian Financial Review involving the cannabis and psychedelics company's non-executive chair, Adam Blumenthal.

Shares in the small-cap company tumbled 9% to 12.3 cents apiece before being placed into a trading halt. The frozen share price will remain in place until Creso can respond to the ASX's price query.

However, the intriguing news today relates to the office raid of Mr Blumenthal.

A dollar sign embedded in ice, indicating a share price freeze or trading halt

Image source: Getty Images

Creso Pharma share price falls amid ASIC investigation at EverBlu

Investors weren't playing around this afternoon after they got word of what was going on in Sydney today. It appears shareholders were quite nervous about the news that Creso Pharma's non-exec chair, Blumenthal, had his office raided by the Australian Federal Police (AFP) today.

To be clear, the office raided was not that of Creso Pharma. Rather, it was Blumenthal's boutique corporate advisory company, EverBlu Capital.

According to reports, officers were adorning gloves and flicking through files to assist the Australian Securities and Exchange Commission (ASIC) with an investigation. Neither the AFP nor ASIC have shed any further light on exactly what the investigation is in relation to.

The EverBlue Capital team was involved in advising Creso Pharma on its bonus options issue in October. My colleague, Zach, covered this at the time, outlining how the financial instrument could be used to raise capital if exercised.

Talk about timing

As fate would have it, the precarious situation has come to light mere days after Creso Pharma handed down its trading update for Q4 FY21. Overall, the update was reasonably positive for the company, pushing The Creso Pharma share price higher.

Furthermore, the quarter saw the company achieve strong revenue growth in its Swiss operations. However, the market's sentiment might now be tainted by the latest developments involving Adam Blumenthal.

The Creso Pharma share price will remain halted until an announcement is provided, or until the commencement of trade on Thursday, 18 November 2021.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Broker Notes

Up 1,250% in a year, why 4DMedical shares can keep charging higher

A top analyst forecasts more outperformance from the surging shares.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

Down 31%: Is there any chance of a rebound from ResMed shares?

The ASX healthcare share has lost 31% over the past 12 months.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

If I invested $5,000 in this ASX healthcare stock 12 months ago, I'd have over $67k today!

This ASX healthcare stock is bucking the trend.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Stronger revenue numbers signal potential upside.

Read more »

doctor making thumbs up gesture and holding vial labelled 'covid-19 vaccine' representing covid shares
Healthcare Shares

What to expect from CSL shares this reporting season

Will CSL surprise or disappoint investors?

Read more »

laboratory workers looking disappointed
Healthcare Shares

These battered ASX healthcare shares could bounce back

Strong moats and bullish brokers put these ASX stocks back on watch.

Read more »